BioAge Labs, Inc. (BIOA)
BIOA Stock Price Chart
Explore BioAge Labs, Inc. interactive price chart. Choose custom timeframes to analyze BIOA price movements and trends.
BIOA Company Profile
Discover essential business fundamentals and corporate details for BioAge Labs, Inc. (BIOA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
26 Sept 2024
Employees
62.00
Website
https://bioagelabs.comCEO
Kristen Fortney
Description
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
BIOA Financial Timeline
Browse a chronological timeline of BioAge Labs, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.64, while revenue estimate is $777.50K.
Earnings released on 6 Aug 2025
EPS came in at -$0.60 falling short of the estimated -$0.56 by -7.14%, while revenue for the quarter reached $2.41M , beating expectations by +177.24%.
Earnings released on 6 May 2025
EPS came in at -$0.36 surpassing the estimated -$0.52 by +30.77%, while revenue for the quarter reached $1.45M , beating expectations by +150.17%.
Earnings released on 20 Mar 2025
EPS came in at -$1.97 falling short of the estimated -$0.58 by -239.66%.
Earnings released on 7 Nov 2024
EPS came in at -$6.70 falling short of the estimated -$0.72 by -830.56%.
Earnings released on 26 Sept 2024
EPS came in at -$1.80 .
Earnings released on 31 Mar 2024
EPS came in at -$1.74 .
Earnings released on 31 Dec 2023
EPS came in at -$2.81 .
Earnings released on 30 Sept 2023
EPS came in at -$1.96 .
Earnings released on 30 Jun 2023
EPS came in at -$2.30 .
Earnings released on 31 Mar 2023
EPS came in at -$1.48 .
BIOA Stock Performance
Access detailed BIOA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.